Brody, B.D., Park, N., Christian, A., Shaffer, C.W., Smetana, R., Kotbi, N., et al. (2024) Ketamine for Major Depressive Disorder during an Inpatient Psychiatric Admission: Effectiveness, Adverse Events, and Lessons Learned. Journal of Affective Disorders, 351, 293-298.
https://doi.org/10.1016/j.jad.2024.01.207

has been cited by the following article:

• TITLE: Treatment Resistant Depression, Ketamine versus ECT

  AUTHORS: Smita Agarkar

  KEYWORDS: Treatment Resistant Depression, Ketamine, ECT

  JOURNAL NAME: Open Journal of Psychiatry, Vol.14 No.4, July 29, 2024

  ABSTRACT: Recent studies have highlighted the increase in treatment resistant depression. Of particular concern is the rising trend of depression and suicide rates among Young Adults. Ketamine was approved for treatment resistant depression in 2019 by the US Food and Drug Administration. It received an additional indication for treatment of suicidality. While intranasal Ketamine is approved for depression, recent data about intravenous infusion of Ketamine in controlled inpatient settings has been promising. ECT has a long-standing trend for being used for resistant depression and recent comparison trials have revealed positive results when head-to-head comparisons are made with Ketamine. Future studies need to focus on patient selection and wherein treatment algorithm should Ketamine be selected as treatment modality.